BIOLINERX
Careers | Contact Us
search

Press Releases
August 6, 2018
Management to hold a conference call at 10:00 a.m. EDT
July 30, 2018
30-50 patients in additional arm will be investigated under the collaboration

Results from combination of BL-8040 and KEYTRUDA® (pembrolizumab) in COMBAT/KEYNOTE-202 study will be reported in H2 2018 as planned
June 18, 2018
Data presented at EHA shows significantly improved overall survival compared to historical data

Potential biomarker identified for future patient selection, based on statistically significant correlation between responders and levels of AML blast mobilization to peripheral blood

May 17, 2018
BL-8040 was safe and well tolerated, and all transplanted recipients were successfully engrafted

Full top-line results will be presented at the 23rd EHA Congress

May 17, 2018
BL-8040 in combination with Cytarabine showed significantly improved overall survival compared to historical data

May 16, 2018
Management to hold a conference call at 10:00 a.m. EDT
May 16, 2018
Patent valid through March 2034, with up to five years’ patent term extension
21-30  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next